Stay updated with breaking news from Biontech Fixvac. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase 3 clinical trial evaluating BNT323/DB-1303 in HR+ HER2-low...
Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase 3 clinical trial evaluating...
Investegate announcements from BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
06.11.2023 - Positive clinical data updates across multiple drug classes including antibody-drug conjugate (ADC) candidates BNT323/DB-1303, BNT325/DB-1305, CAR-T candidate BNT211, T cell therapy candidate BNT221 and mRNA cancer vaccine candidate BNT116Progress ...
/PRNewswire/ -- The "Global mRNA Cancer Vaccines Market Opportunity & Clinical Pipeline Insight 2023" drug pipelines has been added to ResearchAndMarkets.com's...